Ertumaxomab: a trifunctional antibody for breast cancer treatment
Authors:
- Philipp KiewePKPhilipp Kiewe
- Eckhard ThielETEckhard Thiel
- 22 September 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 17 (10) , 1553-1558
Abstract
Ertumaxomab is an intact bispecific antibody targeting HER2/neu and CD3 with preferential binding to activating Fcgamma type I/III-receptors, resulting in the formation of a tri-cell complex among tumour cell, T cell and accessory cell. Recently, the antibody demonstrated antitumour efficacy against HER2/neu low-expressing tumours resistant to trastuzumab. Data from a completed Phase I study in metastatic breast cancer patients indicates strong immune responses. Owing to efficient tumour cell destruction by humoral and T-cell-dependent mechanisms, differing from conventional HER2/neu directed treatments, and a potential for long-lasting antitumour immunoreactivity, ertumaxomab is at present investigated within Phase II studies enrolling metastatic breast cancer patients even without HER2/neu gene amplification.Keywords
This publication has 30 references indexed in Scilit:
- Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib MonotherapyJournal of Clinical Oncology, 2008
- Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95Cancer Research, 2008
- Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast CancerClinical Cancer Research, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3)Journal of Histochemistry & Cytochemistry, 2001
- Bispecific Monoclonal Antibodies for Intravenous Treatment of Carcinoma Patients: Immunobiologic AspectsJournal of Hematotherapy, 1995
- Clinical Development of 2B1, a Bispecific Murine Monoclonal Antibody Targeting c-erbB-2 and FcγRIIIJournal of Hematotherapy, 1995
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987
- Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibodyNature, 1985